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Purpose: This study determined the seroprevalence of herpes virus 2 in gravidas 
and the differences between herpes virus 2-infected and healthy gravidas. The 
need to screen gravidas for herpes virus 2 was also evaluated. Materials and 
Methods: A retrospective analysis involving 500 gravidas who underwent herpes 
virus 2 serologic testing and delivery in our hospital between January 2009 and 
August 2010 was performed. All patients in the study group were classified as her-
pes simplex virus 2 (HSV2) positive, and all cases were analyzed with respect to 
the clinical course of the pregnancy, pregnancy outcome, obstetric complications, 
and neonatal outcomes. SPSS software (version 14.0) was used for statistical anal-
ysis. A chi-square test and Student’s t-test were used for statistical analysis. Re-
sults: In the current study, the herpes virus 2 seroprevalence rate in gravidas was 
17%. There was no significant difference in the rates of preterm delivery, prema-
ture rupture of membranes, preterm labor, and intrauterine growth restriction be-
tween the herpes virus 2-infected gravidas and the healthy control group. The rates 
of spontaneous abortion and sexually transmitted disease were higher in the herpes 
virus 2 infection group than the healthy control group. Conclusion: After educat-
ing gravidas on genital herpes and, if gravidas thereafter consent to herpes virus 2 
screening, the risk of neonatal herpes virus 2 infections can be reduced. In addi-
tion, examination of gravidas for sexually transmitted diseases would increase as 
would appropriate treatment.
Key Words:    Herpes virus 2, seroprevalence, pregnancy, sexually transmitted dis-
ease
INTRODUCTION
Herples simplex virus (HSV) is an enveloped, double stranded DNA virus perti-
nent to the human herpesvirus family. Although closely related, HSV1 and HSV2 
still contain sufficient differences to enable type identification and serodiagnosis, 
however both viruses are neurotropic,1 attaching themselves to a host epidermal or 
mucosal cell and then transporting the enveloped virions via axons to the nuclei of 
the neuronal cells.2Il Dong Kim, et al.
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Herpes virus 2 serologic tests were performed between 
27 and 29 weeks gestation. Gravidas were educated about 
genital herpes, and, after informed consent for a herpes vi-
rus 2 serologic test was granted, a blood sample was ob-
tained. At 38 weeks gestation and at the time of delivery, 
herpes lesions were confirmed based on genital inspection 
and answers to questions regarding herpes symptoms. If 
there were symptoms of vaginosis or abnormal vaginal se-
cretions antepartum, sexually transmitted disease (STD)   
testing was performed. Human papillomavirus (HPV) test-
ing was performed early during the pregnancy upon request 
from the gravida.  
SPSS software (version 14.0) was used for statistical anal-
ysis. The average and standard deviations are shown. A chi-
square test and Student’s t-test were used for statistical anal-




Comparison of maternal demographic data 
The mean age of the gravidas was 31.6±4.6 years in the 
HSV2 positive group and 30.4±4.2 years in the healthy con-
trol group. There was a significant difference in the ages of 
the gravidas between the two groups (p<0.05). The mean 
gestational age of the gravidas was 38.9±1.4 weeks in the 
HSV2 positive group and 39.2±1.1 weeks in the healthy 
control group. Among 85 gravidas in the HSV2 positive 
group, 56 were primiparas and 29 were multiparas; in the 
control group, 296 gravidas were primiparas and 119 were 
multiparas. The gender ratio of neonates were 1 : 1 in both 
the HSV2 positive group (42 males and 43 females) and the 
healthy control group (205 males and 210 females). The av-
erage birth weight of neonates was 3.2±0.4 kg in the HSV2 
positive group and 3.2±0.3 kg in the healthy control group. 
There were no significant differences in gestational age, ra-
tio of primiparas to multiparas, gender ratio of neonates, and 
birth weights of neonates between the two groups (Table 1). 
Comparison of seropositivity 
No gravidas were rubella IgM-positive in either group. Sev-
enty-eight gravidas (91.8%) in the HSV2 positive group and 
369 of 415 gravidas (88.9%) in the health control group 
were rubella IgG-positive. Seventy-eight gravidas (91.8%) 
in the HSV2 positive group and 386 gravidas (93.0%) in the 
healthy control group were positive for anti-varicella anti-
body. Six of the 85 gravidas (7.1%) in the HSV2 positive 
The two viruses, HSV1 and HSV2, spread themselves 
through different means. The former being via salivary and 
respiratory contact whiles the latter through genital contact. 
Cases of HSV1 infections are seen worldwide and do not 
discriminate by age. A human with a primary infection may 
manifest orolabial herpes, gingivostomatitis, pharyngitis and 
genital herpes.3
One of the most commonly seen sexually transmitted 
disease would be an HSV infection of the genital tract. Ac-
cording to serologic test results, there is a 2% incidence of 
HSV1 or HSV2 infections among women during pregnan-
cy,4 most of them being asymptomatic, as with non-preg-
nant women.1 It has also been observed that while postnatal 
infections are rare (though possible), neonatal infections are 
usually acquired in utero; during the intrapartum period via 
exposure to the virus in the genital tract.5 Long-term neuro-
logic sequelae has been noted in about 20% of neonatal 
herpes survivors.6 However neonatal mortality rates have 
decreased substantially in the last two decades. More spe-
cifically, disseminated disease and central nervous system 
disease mortality rates fell 30% and 4% each.6
Herpes virus screening of gravidas reduces neonatal her-
pes infection rates and the need for antiviral drug treatment 
at the time of delivery. Thus, we studied the presence of 
HSV2 infections in gravidas by serological methods, and 
determined the differences between infected and healthy 
groups of gravidas. Furthermore, we evaluated the need for 
herpes virus 2 serologic screening in gravidas.
MATERIALS AND METHODS
　　　
A retrospective analysis including 500 gravidas who under-
went HSV2 serologic testing and gave birth at our hospital, 
was carried out between January 2009 and August 2010. The 
study group was classified as anti-herpes virus 2 antibody-
positive, and the following variables were analyzed: clinical 
course of pregnancy, pregnancy outcome, obstetric compli-
cations, and neonatal outcomes. The clinical course and out-
comes of pregnancy were assessed for gestational age at de-
livery and incidence of fetal loss. Obstetric complications 
were assessed according to rates of intrauterine growth re-
striction, premature rupture of membranes, preterm deliver-
ies, and preterm labor. Routine prenatal tests included tests of 
rubella, varicella, and hepatitis B (HB) antibody titers, and 
human immunodeficiency virus (HIV) and venereal disease 
research laboratory (VDRL) tests. Herpes Simplex Virus 2 Infection during Pregnancy
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group and 123 of 415 gravidas (29.6%) in the healthy con-
trol group had a history of abortions. There was a signifi-
cant difference in the abortion rates between the 2 groups 
(p<0.05). Two of 85 gravidas (2.3%) in the HSV2 positive 
group and 15 of 415 gravidas (3.6%) in the healthy control 
group had preterm labor. Eighteen gravidas (21.2%) in the 
HSV2 positive group and 73 gravidas (17.6%) in the healthy 
control group had premature rupture of membranes. Seven 
gravidas (8.2%) in the HSV2 positive group and 26 gravi-
das (6.2%) in the healthy control group had preterm deliv-
eries. Fourteen of 85 gravidas (16.4%) in the HSV2 posi-
tive group and 75 of 415 gravidas (18.0%) in the healthy 
control group were diagnosed with intrauterine growth re-
tardation. Three of 85 newborns (3.5%) in the HSV2 posi-
tive group and 6 of 415 neonates (1.4%) in the healthy con-
trol group were admitted to the neonatal ICU (Table 4). 
There were no significant differences in the rates of preterm 
labor, premature rupture of membranes, preterm delivery, 
intrauterine growth retardation, and neonatal ICU admis-
sion between the two groups.
DISCUSSION
This is the first study to attempt to determine the prevalence 
group and 21 of 415 gravidas (5.1%) in the healthy control 
group were HBsAg-positive. Sixty-four gravidas (75.3%) in 
the HSV2 positive group and 308 gravidas (74.2%) in the 
healthy control group were HBsAb-positive. There were no 
significant differences in rubella and varicella antibody ti-
ters, as well as the HBsAg-positive, and HBsAb-positive 
rates between the two groups of gravidas (Table 2). 
Comparison of sexually transmitted pathogens 
No gravidas were HIV-positive or VDRL-positive in either 
group. One gravida (1.2%) in the HSV2 positive group and 
three gravidas (0.7%) in the healthy control group had geni-
tal condyloma infections. Four of 14 gravidas (28.6%) in 
the HSV2 positive group and 13 of 35 gravidas (37.1%) in 
the healthy control group had HPV infections. There were 
no significant differences in condyloma and HPV infections 
between the two groups of gravidas. Twelve of 17 gravidas 
(70.6%) in the HSV2 positive group and 23 of 49 gravidas 
(46.93%) in the control group had positive sexually trans-
mitted disease screens (Table 3). There was a significant 
difference in sexually transmitted disease screening be-
tween the two groups (p<0.05). 
Comparison of obstetric complications 
Thirty-three of 85 gravidas (38.8%) in the HSV2 positive 
Table 1. Comparison of Maternal Demographic Data 
Herpes virus 2 antibody-positive Control  p value
Maternal age (yrs) 31.6±4.6 30.4±4.2 0.014
    <20 0 (0)   5 (1.2)
    21-24   4 (4.7) 24 (5.7)
    25-29   27 (31.7) 162 (39.0)
    30-34   30 (35.2) 149 (35.9)
    35-40   20 (23.5)   68 (16.3)
    ≥41   4 (4.7)   7 (1.6)
Gestational age (wks) 38.9±1.4 39.2±1.1 0.076
Primipara-to-multipara ratio 56 : 29 296 : 119 0.317
Gender (M : F) 1 : 1 1 : 1 0.998
Birth weight (kg)  3.2±0.4  3.2±0.3 0.492
Values are presented as the mean±SD or number (%). 
Table 2. Comparison of Seropositivity
Herpes virus 2 antibody-positive Control p value
Rubella IgM 0 0
Rubella IgG 78 (91.8) 369 (88.9) 0.437
Varicella antibody-positive 78 (91.8) 386 (93.0) 0.648
HBsAg-positive 6 (7.1) 21 (5.1) 0.434
HBsAb-positive 64 (75.3) 308 (74.2) 0.892
HB, hepatitis B.
Values are presented as a number (%).Il Dong Kim, et al.
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symptoms.7 75-85% of recurrences of genital infections are 
asymptomatic in infected women, however individuals in-
fected with herpes virus are generally unaware of the inci-
dent; as a mere 5-15% of people report an infection.8,9 There-
fore gravidas, early in pregnancy, should be questioned for 
signs that may indicate genital herpes, not excluding pro-
dromal symptoms. Suspected herpes virus infections should 
then be confirmed through viral or serological testing, as 
clinical presentation alone has a sensitivity of 40%, speci-
ficity of 99% and a false positive rate of 20%.10 Only type-
of HSV2 infections in gravidas in Korea. In the current 
study, the HSV2 positive rate was 17% in Korean gravidas. 
The HSV2 positive rate in gravidas from several countries 
has been surveyed. The HSV2 positive rate was higher in 
African countries, such as Uganda (67.2%)33 and Zimba-
bwe (49.1%).34 In contrast, the HSV2 positive rates in Aus-
tralia (13.6%)37 and the US (22%)36 are similar to the rate 
now shown for Korea (17%) (Table 5).
Compared to women with primary Herpes Virus 2 infec-
tions, women with non-primary infections reflect milder 
Table 3. Comparison of Sexually Transmitted Pathogens 
Herpes virus 2 antibody-positive  Control  p value
HIV 0 0
VDRL 0 0
STD    12/17 (70.5)     23/49 (46.9) 0.006
    Chlamydia 3 1
    Mycoplasma 2 3
    Trichomonas 1 0
    Ureaplasma 6 19
HPV       4/14 (28.5)     13/35 (37.1) 0.642
    Genotype16 1 5
    Genotype 18 1 1
    Genotype 32 0 1
    Genotype 34 0 1
    Genotype 53 1 0
    Genotype 53.68 1 0
    Genotype 56 0 1
    Genotype 62 0 1
    Genotype 66 0 1
    Genotype 74 0 1
    Genotype 90 0 1
Condyloma            1 (1.17)            3 (0.72) 0.669
HIV, human immunodeficiency virus; VDRL, venereal disease research laboratory; STD, sexually transmitted disease; HPV, human papillomavirus.
Values are presented as a number (%). 
Table 4. Comparison of Obstetric Complications  
Herpes virus 2 antibody-positive Control p value
Abortion 33 (38.8) 123 (29.6) 0.045
    1* 19 86
    2   8 26
    3   3   8
    4   2   2
    5   1   1
Preterm labor 2 (2.3) 15 (3.6) 0.559
PROM 18 (21.2)   73 (17.6) 0.442
Preterm delivery 7 (8.2) 26 (6.2) 0.528
IUGR 14 (16.4)   75 (18.0) 0.718
NICU 3 (3.5)   6 (1.4) 0.185
PROM, preterm rupture of membrane; IUGR, intrauterine growth retardation; NICU, neonatal intensive care unit. 
Values are presented as a number (%).
*The number of abortions a given gravida has had. Herpes Simplex Virus 2 Infection during Pregnancy
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mary outbreak during delivery.22
Herpes virus 1 accounts to about one-third to a half of 
cases of neonatal herpes,22,23 though amongst gravidas who 
suffer recurrent lesions during delivery, their transmission 
rate with a vaginal delivery is only of 3%.17 Beyond this, 
only 2 out of every 10000 gravidas with a history of recur-
rent disease, but no visible lesions during delivery, are in 
risk of transmission.22,24
Maternal herpes virus acquisitions during pregnancy are, 
unfortunately, not addressed by antiviral suppression and 
cesarean delivery, which fail 70-80% of the time to prevent 
neonatal herpes infections. In cases in which the herpes vi-
rus infections are sub-clinical, nearly 90% of these are not 
accounted by the methods mentioned above.4,23
Increased risk of spontaneous abortion has always been 
associated with herpes virus, though this has been found to 
be contradictory to recent studies.25 In the current study, 
however, the spontaneous abortion rate was correlated with 
a statistically significant increase in the herpes virus 2 anti-
body-positive group, in comparison with the control group. 
The transplacental passage of the virus is rare, and herpes 
virus 2 infections are not associated with stillbirths.26
Neonatal chorioretinitis, microcephaly and skin lesions 
are very occasionally associated with primary outbreaks in 
the first trimester of pregnancy.27 Neonatal herpes virus in-
fections can fall under 3 different classifications, those be-
ing disseminated disease (25%) central nervous system dis-
ease (30%), and  disease limited to the skin, eyes, or mouth 
(45%).5 Though uncommon, neonatal herpes encephalitis is 
known as severe with a mortality rate of 4-14% and long 
term neurologic sequelate (56-69%).1,28-32 According to a 
large cohort study, gravidas are much less likely to transmit 
herpes virus infections to their infants when they give birth 
by cesarean section.22 Only 1.2% of infants, from gravidas 
with herpes virus infections detected at the time of delivery, 
received neonatal herpes infections when delivered by ce-
specific serologic testing can distinguish between primary, 
non-primary, and recurrent infections with certainty.11 About 
75% of women with recurring genital herpes virus infec-
tions suffer at least one recurrence during pregnancy whiles 
approximately 14% of them will show prodromal symp-
toms or clinical recurrence during delivery.12,13 Thus, wom-
en with a history of a herpes virus infection should be ex-
amined for genital herpetic lesions during labor and delivery. 
In the late antepartum period, there may be fever and uri-
nary symptoms associated with herpes virus infections, but 
often without local symptoms, which results in missed di-
agnoses.3
Serologic testing for herpes virus 2 will identify gravidas 
with sub-clinical herpes virus 2 infections who were previ-
ously undiagnosed.14 According to The American College 
of Obstetricians and Gynecologists recommendations, rou-
tine HSV screening of gravidas is not recommended. A sur-
vey conducted on a sample of 100 gravidas, regarding their 
knowledge and attitude on genital herpes, showed that 80% 
of them desired to be tested for HSV and 76% also encour-
aged their sexual partners to be tested.15 Based on this study, 
an examination for herpes virus is readily accepted in gravi-
das upon receiving education on genital herpes. Ideally, 
most, if not all gravidas are examined for herpes virus in-
fection in addition to gravidas who are scheduled for a re-
peat cesarean section. To evaluate the cost-effectiveness of 
different screening protocols for gravidas, several analyses 
have been made on how the incidence of neonatal herpes 
virus infections is reduced by those.16-20
As opposed to recurrent infections, primary genital her-
pes infections present a higher risk for perinatal transmis-
sion, as the mean duration of viral shedding for women 
with intreated primary HSV2 is 15 days.21 Moreover 90% 
of women with primary infections also showed cervical 
shedding by viral culture.21 However there is a 30-60% risk 
of vertical transmission to the neonate when there is a pri-
Table 5. Herpes Virus 2 Antibody-Positive Rate in Gravidas
Investigator      Country Herpes virus 2 antibody-positive
Nakubulwa, et al.
33      Uganda     67.2 (168/250)
Munjoma, et al.
34           Zimbabwe     49.1 (167/340)
Kapranos, et al.
35    Greece 43.2 (41/95)
Xu, et al.
36 USA     22.0 (138/626)
Sasadeusz, et al.
37        Australia       13.6 (186/1371)
Berntsson, et al.
38      Sweden   10.4 (31/299)
Ozdemir, et al.
39     Turkey     8.2 (13/158)
Current study   Korea   17.0 (85/500)
Values are presented as a % (number).Il Dong Kim, et al.
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in the United States. Sex Transm Dis 2004;31:311-6.
10. Centers for Disease Control and Prevention, Workowski KA, Ber-
man SM. Sexually transmitted diseases treatment guidelines, 
2006. MMWR Recomm Rep 2006;55(RR-11):1-94.
11. Diamond C, Selke S, Ashley R, Benedetti J, Corey L. Clinical 
course of patients with serologic evidence of recurrent genital her-
pes presenting with signs and symptoms of first episode disease. 
Sex Transm Dis 1999;26:221-5.
12. Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez 
PJ, et al. Valacyclovir prophylaxis to prevent recurrent herpes at 
delivery: a randomized clinical trial. Obstet Gynecol 2006;108: 
141-7.
13. Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL, 
et al. A double-blind, randomized, placebo-controlled trial of acy-
clovir in late pregnancy for the reduction of herpes simplex virus 
shedding and cesarean delivery. Am J Obstet Gynecol 2003;188: 
836-43.
14. Gardella C, Barnes J, Magaret AS, Richards J, Drolette L, Wald A. 
Prenatal herpes simplex virus serologic screening beliefs and prac-
tices among obstetricians. Obstet Gynecol 2007;110:1364-70.
15. Vonau B, Low-Beer N, Barton SE, Smith JR. Antenatal serum 
screening for genital herpes: a study of knowledge and attitudes of 
women at a central London hospital. Br J Obstet Gynaecol 1997; 
104:347-9.
16. Cleary KL, Paré E, Stamilio D, Macones GA. Type-specific 
screening for asymptomatic herpes infection in pregnancy: a deci-
sion analysis. BJOG 2005;112:731-6.
17. Thung SF, Grobman WA. The cost-effectiveness of routine ante-
natal screening for maternal herpes simplex virus-1 and -2 anti-
bodies. Am J Obstet Gynecol 2005;192:483-8.
18. Baker D, Brown Z, Hollier LM, Wendel GD Jr, Hulme L, Griffiths 
DA, et al. Cost-effectiveness of herpes simplex virus type 2 sero-
logic testing and antiviral therapy in pregnancy. Am J Obstet Gy-
necol 2004;191:2074-84.
19. Barnabas RV, Carabin H, Garnett GP. The potential role of suppres-
sive therapy for sex partners in the prevention of neonatal herpes: a 
health economic analysis. Sex Transm Infect 2002;78:425-9.
20. Rouse DJ, Stringer JS. An appraisal of screening for maternal 
type-specific herpes simplex virus antibodies to prevent neonatal 
herpes. Am J Obstet Gynecol 2000;183:400-6.
21. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, et 
al. Treatment of first episodes of genital herpes simplex virus in-
fection with oral acyclovir. A randomized double-blind controlled 
trial in normal subjects. N Engl J Med 1983;308:916-21.
22. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect 
of serologic status and cesarean delivery on transmission rates of 
herpes simplex virus from mother to infant. JAMA 2003;289:203-9. 
23. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, et 
al. A controlled trial comparing vidarabine with acyclovir in neo-
natal herpes simplex virus infection. Infectious Diseases Collabor-
ative Antiviral Study Group. N Engl J Med 1991;324:444-9.
24. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, et 
al. Neonatal herpes simplex virus infection in relation to asymp-
tomatic maternal infection at the time of labor. N Engl J Med 
1991;324:1247-52.
25. Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong 
V, Olsen J, Sørensen HT. Adverse pregnancy outcome in women 
exposed to acyclovir during pregnancy: a population-based obser-
vational study. Scand J Infect Dis 2003;35:255-9.
26. Eskild A, Jeansson S, Stray-Pedersen B, Jenum PA. Herpes sim-
sarean section as opposed to a 7.7% of those delivered vag-
inally.22
A comparison of the clinical characteristics of HSV2 
positive gravidas compared with the healthy control group 
revealed that there were no significant differences in the 
rates of preterm delivery, premature rupture of membranes, 
preterm labor, intrauterine growth restriction, and cesarean 
section. In this study, the HSV2 positive group did not have 
higher hepatitis B, varicella, or rubella antibody titers than 
the healthy control group. However, the HSV2 positive 
group had a statistically significantly higher rate of positive 
sexually transmitted disease than the healthy control group. 
Thus, we recommend sexually transmitted disease screen-
ing in HSV2 positive gravidas to help discover the presence 
of sexually transmitted disease.
A limitation of the current study was that herpes virus in-
fections and herpes virus antibodies were not assessed in 
infants born to HSV2 positive gravidas.
Educating gravidas on genital herpes and herpes virus 2 
screening might reduce the probability of transmitting her-
pes virus 2 infections to neonates. In addition, educating 
gravidas on herpes virus 2 infections could facilitate sexual-
ly transmitted disease screening and appropriate treatment. 
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